News
-
-
PRESS RELEASE
Inside Information / Operations of the issuer (acquisitions, sales...)
Median Technologies receives FDA 510(k) clearance for eyonis® LCS, the first AI tech-based detection and diagnosis device for lung cancer screening. The device aims to redefine lung cancer screening with high accuracy and potential to save lives -
-
-
-
-
-
PRESS RELEASE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Median Technologies discloses total voting rights & shares as of Nov 30, 2025, in compliance with French regulations. Company pioneers AI for cancer diagnosis & treatment -
-
